DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today reported that preliminary revenue results continued strong in the fourth quarter (ended June 30, 2012), coming in at approximately $2,328,000. Given the preliminary fourth quarter revenues noted above, the company’s preliminary revenue results for the fiscal year ended June 30, 2012, will be approximately $9,289,000, a new record, 17% over the prior year, and greater than the $9.1 million guidance announced after the third quarter results in May.
